MétaCan
Menu
Back to cohort

A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial

2005· article· en· W1343435 on OpenAlexaff
Waldo Belloso, Silvina Ivalo, Jorge Benetucci, D Pugliese, Daniela Garone, Pedro Cahn, Alejandro Krolewiecki, Arnaldo Casiró, Isabel Cassetti, Rosa Bologna, Adriana Durán, Javier Toibaro, Armin Rieger, B Vago, Nathan Clumeck, Kabamba Kabeya, Curtis Cooper, S Dufresne, R Lalonde, Sharon Walmsley, Jan Gerstoft, L Mathiesen, Henrik Nielsen, Niels Obel, Christian Pedersen, Adriano Lazzarin, Antonella Castagna, Johan N. Bruun, José M. Gatell, J.A. Arnaiz, Anders Blaxhult, Leo Flamholc, Magnus Gisslén, Pietro Vernazza, Joshua S. Bingham, B Peters, Brian Gazzard, Mark Nelson, Sherry Johnson, M Youle, Jan Weber, G Scullard, Indira Brar, V Bouzi, Andre Brutus, Dushyantha Jayaweera, Miguel Mogyoros, Barry M. Rodwick, David Stein, Andrew Wiznia, Robert A. Schwartz, M G Vandenberg-Wolf, Ellen Tedaldi, Ulrik Bak Dragsted, Mike Youle, Zoë Fox, M Losso, Andrew Hill, Jens Lundgren

Bibliographic record

VenueAntiviral Therapy · 2005
Typearticle
Languageen
FieldMedicine
TopicHIV/AIDS drug development and treatment
Canadian institutionsToronto Western HospitalToronto General HospitalSt. Thomas HospitalUniversity Health NetworkOttawa Hospital
FundersMalmö HögskolaSahlgrenska UniversitetssjukhusetTemple UniversityUniversity of Miami
KeywordsRitonavirLopinavirDiscontinuationLopinavir/ritonavirMedicineSaquinavirInternal medicineAdverse effectRandomized controlled trialGastroenterologyIntention-to-treat analysisPopulationViral loadHuman immunodeficiency virus (HIV)ImmunologyAntiretroviral therapy

Abstract

fetched live from OpenAlex

OBJECTIVE: To assess the rate of protocol-defined treatment failure and safety of lopinavir/ritonavir (LPV/r) and saquinavir/ritonavir (SAQ/r). DESIGN: Open-label, prospective, randomized (1:1), international multi-centre trial. METHODS: Adult HIV-1-infected patients were assigned LPV/r 400/100 mg twice daily or SAQ/r 1000/100 mg twice daily with two or more nucleoside reverse transcriptase inhibitors (NRTIs)/non-NRTIs. All patients, whether on or off the assigned treatment, were followed for 48 weeks. RESULTS: Of 339 randomized patients, 324 initiated assigned treatment (intention-to-treat/exposed [ITT/e] population). At 48 weeks, treatment failure occurred in 29/163 (18%) and 53/161 (33%) of patients in the LPV/r and SAQ/r arms, respectively (ITT/e, P = 0.002, log rank test). In an analysis that also considered those patients who discontinued treatment as having failed treatment (ITT/e/discontinuation = failure), 40/161 (25%) LPV/r-treated individuals versus 63/161 (39%) SAQ/R-treated individuals failed treatment (P = 0.005, log rank test). Discontinuation of the assigned treatment occurred in 23/163 (14%) patients in the LPV/r-treated group, compared with 48/161 (300%) in the SAQ/r-treated group (ITT/e; P = 0.001). The primary reasons for premature discontinuation were non-fatal adverse events (LPV/r: 12/163; SAQ/r: 21/161) and patients' choice (LPV/r: 7/163; SAQ/r: 8/161). In the on-treatment analysis of time to treatment failure, no difference was observed between the two arms (P = 0.27, log rank test). CONCLUSION: LPV/r had better antiretroviral effects compared with SAQ/r at the doses and in the formulations studied. This may have been a result of patients' preferences and ability to adhere to assigned therapy, rather than a result of differences in the intrinsic potency of the study protease inhibitors.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.026

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.004
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.038
GPT teacher head0.340
Teacher spread0.302 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations68
Published2005
Admission routes1
Has abstractyes

Explore more

Same venueAntiviral TherapySame topicHIV/AIDS drug development and treatmentFrench-language works237,207